As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

On this weeks Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a ...

Catalyst Flex, a functional service provider (FSP) solution of Catalyst Clinical Research, is a multi-therapeutic niche contract research organization (CRO)with flexible, fit-for-purpose offerings in ...

On this weeks Business Of Biotech episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new products, write Noël Theodosiou and Patrick O. Gee.

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without risking exclusive rights over valuable assets, writes Richard Gold.

What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and private equity investment in oncology, according to experts at KPMG.

A key focus of Part III in this clinical trial payment series is the tax implications of trial payments. This article emphasizes that while reimbursements for out-of-pocket expenses are tax-exempt and ...

Gene therapy is revolutionizing medicine with its potential to cure genetic disorders. As approvals rise, so do concerns about accessibility, with million-dollar price tags limiting patient access.